Research programme: thrombin inhibitors - Merck & Co
Latest Information Update: 05 Oct 2006
At a glance
- Originator Merck & Co
- Mechanism of Action Thrombin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 05 Oct 2006 Discontinued - Phase-I for Thrombosis in USA (unspecified route)
- 03 Apr 2003 Phase-I clinical trials in Thrombosis in USA (unspecified route)
- 03 Apr 2003 Clinical candidate has been selected